^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Vaccine Therapy in Treating Patients With Metastatic Solid Tumors

Excerpt:
...The magnitude of antibody levels will be assessed to the vaccine and HER-2 over-expressing cells (e.g.,BT474). ...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

Excerpt:
Thirty of 114 patients (26%; 95% CI, 19% to 35%) with HER2 amplification/overexpression had objective responses to treatment with trastuzumab plus pertuzumab (two CR, 28 PR). Objective responses were seen in nine primary tumor types: colorectal, bladder, biliary, salivary gland, NSCLC, pancreas, ovary, prostate, and skin.
DOI:
10.1200/JCO.2017.75.3780